We use cookies on this site to enable your digital experience. By continuing to use this site, you are agreeing to our cookie policy. close

5th Circuit Affirms Texas’ FDA Defense Law In Abilify Withdrawal Suit

(October 30, 2018, 1:16 PM EDT) -- NEW ORLEANS — The Fifth Circuit U.S. Court of Appeals on Oct. 29 affirmed that a pro se plaintiff’s withdrawal injury claim from the atypical antipsychotic Abilify is barred by a...
To view the full article, register now.